Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Arrowhead Pharmaceuticals

Cytokinetics

Halozyme Therapeutics

Jazz Pharmaceuticals

SpringWorks Therapeutics Inc

Viking Therapeutics

While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn't received the same fervor.

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

ZUG, Switzerland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Christian Rommel, Ph.D., to its Board of Directors at the Company's annual general meeting to be held this year.

CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Amylyx Pharmaceuticals

Vertex Pharmaceuticals

Investing in biotechnology (biotech) stocks is often thought of as being too risky for most investors. That's not necessarily the case.

The Top 3 Biotech Stocks to Buy in March 2024

Last month, the company's first treatment received clearance from European Union regulators, having previously been approved in the U.S. and the U.K. Its cash burn was lower than expected in the fourth quarter, and it made progress on new product development. The stock is still likely to experience significant volatility for the foreseeable future.

Here's Why CRISPR Therapeutics Stock Climbed 34% in February

Moderna

ChatGPT stock predictions could be more than shots in the dark by AI. The processing and inferential power of artificial intelligence progresses seemingly exponentially every day.

ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential

CRISPR Therapeutics is launching its first medicine, which is bullish. It'll also be giving investors updates on a couple of important programs.

CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst

Biotech stocks have long been a speculative, albeit rewarding way to invest in the advancement of medical technology. This industry has a wide range of companies, from start-up firms that are researching their first treatment to pharmaceutical giants that are among the largest and most powerful companies in the world.

3 Biotech Stocks Bound to Blast Off By 2029

Amgen

Axsome Therapeutics

CRISPR Therapeutics' recent major regulatory win could be the first of many. Axsome Therapeutics should ride the wave from its rich late-stage pipeline.

3 Biotech Stocks to Buy and Hold for the Next 10 Years

CRISPR Therapeutics AG NASDAQ: CRSP made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. NASDAQ: VRTX received the first-ever FDA approval for a gene-editing therapy for sickle-cell disease (SCD) called Casgevy on Dec 8, 2023. This FDA approval was a boon to the medical sector and notably for gene therapy focused biotechs like Intellia Therapeutics Inc. NASDAQ: NTLA and Beam Therapeutics Inc. NASDAQ: BEAM.

Is CRISPR Therapeutics the NVIDIA of gene editing?

CRISPR Therapeutics just wowed the market by launching its first drug. Caribou Biosciences is nowhere near an attempt at a launch.

Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR Therapeutics has experienced significant growth in the past five years, with its stock price soaring and then stabilizing around $80. The company has achieved regulatory approval for its CRISPR-based therapy for sickle cell disease and beta-thalassemia and has a diverse pipeline targeting various diseases. Investing in CRISPR Therapeutics requires risk tolerance and a long-term perspective, as the road to commercial success is complex and uncertain.

Crispr Therapeutics: Cautiously Optimistic

CRISPR Therapeutics AG (NASDAQ:CRSP) Citi 2024 Virtual Oncology Leadership Summit Conference February 21, 2024 1:00 PM ET

CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conference (Transcript)

— CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain —

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Intellia Therapeutics

Cathie Wood's biggest bet in her healthcare fund is on a gene editing company. Gene editing has the potential to offer functional cures for serious diseases, so it could be a gamechanger.

Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought

Tesla

Unity Software

Cathie Wood stocks make headlines for their potential to be at the leading edge of disruptive technologies and generate high returns. Yet, Wood's flagship ARK Innovation ETF (NYSEARCA: ARKK ) has declined 8% year-to-date (YTD).

3 Stocks That Cathie Wood Is Loving Now: February 2024

CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last?

ZUG, Switzerland and BOSTON, Feb. 15, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Citi 2024 Virtual Oncology Leadership Summit on Wednesday, February 21, 2024, at 1:00 p.m. ET.

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

bluebird bio

GoodRx Holdings

Gilead Sciences

Sarepta Therapeutics

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.

Gene therapy: Why does it cost millions for a single treatment?

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and diabetes, and further accelerate our auto-immune and in vivo gene writing programs - - Further strengthens balance sheet with pro forma cash position >$2.1 billion - ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it has entered into an investment agreement for the sale of approximately $280 million of its common shares (the “Shares”) to a select group of institutional investors in a registered direct offering, at a price per share of $71.50, representing a premium of greater than 10% to CRISPR Therapeutics' 30-day volume-weighted average price. The financing is expected to close on or about February 27, 2024, subject to customary closing conditions.

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

— Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment —

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Coinbase

UiPath

Roku

Block

Zoom Video

Wood's Ark Invest portfolio owns a large number of stocks but isn't as diversified as it might seem. Ark Invest's top holdings include a biotech stock, a crypto stock, a fintech stock, two AI stocks, and more.

Cathie Wood Has 37% of Her Ark Invest Portfolio Invested in These 7 Stocks

Abbott Labs

The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024.

3 Groundbreaking Healthcare Stocks to Buy for Robust Gains

Intuitive Surgical

CRISPR Therapeutics' recent regulatory approval should be the first of others to come. Intuitive Surgical has a long runway despite recent headwinds from weight-loss medicines.

News for CRISPR Therapeutics Stock (CRSP)